Samsung Biologics said it used a global biopharmaceutical technology event to promote its contract development (CDO) capabilities and earned recognition for its contract manufacturing (CMO) competitiveness.
The company said it took part in the Asia Biopharmaceutical Manufacturing Conference (BMA 2026), held March 11-12 in Singapore. Now in its 13th year, BMA is billed as Asia’s largest biopharmaceutical technology event and is sponsored by global pharma and biotech consulting firm IMAPAC. Organizers said 500 companies and more than 1,200 participants attended.
At the conference, Samsung Biologics presented on its high-concentration formulation development platform, S-HiCon, highlighting its CDO technology. Lim Heon-chang, head of the CDO Development Center’s Formulation Development Group, shared key development cases using S-HiCon, along with challenges and how they were addressed, and introduced the company’s main CDO services.
Launched in 2024, S-HiCon is designed to help clients develop high-concentration formulations by drawing on Samsung Biologics’ formulation development experience. The company said it has secured nine CDO-related technology platforms to meet a range of needs. These include Developick, a platform to assess development feasibility; S-Choice, an in-house cell line platform; and S-Transient, a transient expression platform for candidate materials. The company said it provides tailored CDO services from early development through investigational new drug (IND) applications.
Samsung Biologics also received an award at the ABEA 2026 ceremony held alongside the conference, which it said underscored its CMO competitiveness. ABEA honors companies in the Asia-Pacific region for performance in areas including bioprocessing, logistics and supply chain management, clinical trial expertise, organizational capability and technology over the past year.
The company said it won the Bioprocessing Excellence in Korea Award in recognition of its process development capabilities and global-level quality and production systems, which support clients across the full biopharmaceutical development process through end-to-end services.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.